Myelodysplastic syndromes: recent advances.
暂无分享,去创建一个
M Cazzola | M. Cazzola | C. Mecucci | F. Locatelli | G. Saglio | E. Morra | S. Tura | S. Amadori | G. Visani | G Saglio | E P Alessandrino | S Amadori | F Locatelli | C Mecucci | E Morra | G Visani | S Tura | E. Alessandrino
[1] A. Biondi,et al. Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene. , 2001, Cancer genetics and cytogenetics.
[2] L. Kearney,et al. Combined immunophenotyping and FISH identifies the involvement of B‐cells in 5q‐ syndrome , 2000, Genes, chromosomes & cancer.
[3] S. E. Jacobsen,et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. , 2000, Blood.
[4] G. Meloni,et al. Haematopoietic stem cell transplantation for patients with myelo‐dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) , 2000, British journal of haematology.
[5] M. Cazzola. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome. , 2000, International journal of hematology.
[6] P G Mori,et al. Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy. , 2000, Blood.
[7] O. Ottmann,et al. Cytokine therapy for myelodysplastic syndrome , 2000, Current opinion in hematology.
[8] B. Johansson,et al. Smoking and myelodysplastic syndromes. , 2000, Epidemiology.
[9] Z. Arbieva,et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. , 2000, Blood.
[10] I. Wong,et al. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.
[11] L. Nagarajan,et al. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. , 2000, Blood.
[12] H. Deeg,et al. Hemopoietic stem cell transplantation for myelodysplastic syndrome , 2000, Current opinion in oncology.
[13] H. Deeg,et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. , 2000, Blood.
[14] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[15] Y. Kwong,et al. Familial acute myeloid leukemia with monosomy 7: late onset and involvement of a multipotential progenitor cell. , 2000, Cancer genetics and cytogenetics.
[16] P. Emanuel,et al. Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. , 2000, Blood.
[17] K. Helzlsouer,et al. Use of Hair Dyes, Hematopoietic Neoplasms, and Lymphomas: A Literature Review. I. Leukemias and Myelodysplastic Syndromes , 2000, Cancer investigation.
[18] L. Pagano,et al. Chemotherapy of Secondary Leukemias , 2000, Leukemia & lymphoma.
[19] Benz,et al. Low‐dose melphalan induces favourable responses in elderly patients with high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia , 2000, British journal of haematology.
[20] D. A. Stafford,et al. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. , 1997, Blood.
[21] F. Facchetti,et al. Expression of CD34 by megakaryocytes in myelodysplastic syndromes. , 2000, Haematologica.
[22] T. Tauchi,et al. Transformation of severe aplastic anemia into myelodysplastic syndrome with monosomy 7: monoclonal origin detected by HUMARA gene analysis during the aplastic anemia phase. , 2000, Haematologica.
[23] J. Hernández,et al. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation. , 2000, Haematologica.
[24] V. Santini,et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. , 2000, Haematologica.
[25] C. Rosenfeld,et al. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies , 2000, Leukemia.
[26] J. E. Guimarães,et al. Differences in phenotype, growth factor requirements, pattern of expression of adhesion molecules and rate of apoptosis displayed by three new myeloid sister leukemic cell lines. , 2000, Haematologica.
[27] A. Barrett,et al. Achievements in Understanding and Treatment of Myelodysplastic Syndromes. , 2000, Hematology. American Society of Hematology. Education Program.
[28] B. Rotoli,et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. , 2000, Haematologica.
[29] E. Estey,et al. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. , 2000, Haematologica.
[30] J. Román,et al. A case of atypical myelodysplastic syndrome with a novel reciprocal translocation t(1;12)(q21;p13) , 2000, Haematologica.
[31] A. Corso,et al. Sweet's syndrome and myelodysplasia: two entities with a common pathogenetic mechanism? A case report. , 2000, Haematologica.
[32] C. Peterson,et al. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin. , 2000, Haematologica.
[33] C. Chiodino,et al. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes? , 2000, Haematologica.
[34] A. Pecci,et al. Dihydrofolate reductase activity in the erythroblasts of patients with 5q- syndrome. , 2000, Haematologica.
[35] V. Rosti. The molecular basis of paroxysmal nocturnal hemoglobinuria. , 2000, Haematologica.
[36] G Flandrin,et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] F. Ferrara,et al. Fludarabine, cytarabine, and granulocyte‐colony stimulating factor for the treatment of high risk myelodysplastic syndromes , 1999, Cancer.
[39] John M. Maris,et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.
[40] E. Estey,et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. McBride,et al. A population‐based study of childhood myelodysplastic syndrome in British Columbia, Canada , 1999, British journal of haematology.
[42] Y. Yoshida. The aplasia-myelodysplasia enigma: a re-emerging question. , 1999, International journal of hematology.
[43] M. Taniwaki,et al. Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotype , 1999, Leukemia.
[44] Johnson M Liu,et al. Chromatin remodeling and leukemia: new therapeutic paradigms. , 1999, Blood.
[45] Y. Saunthararajah,et al. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. , 1999, Cancer research.
[46] A. Green. The pathogenesis and management of essential thrombocythaemia. , 1999, Haematologica.
[47] B. Lange,et al. Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. , 1999, Blood.
[48] M. André,et al. DNA demethylating therapy in MDS: The experience with 5-AZA-2 '-deoxycytidine (decitabine). , 1999 .
[49] H. Deeg,et al. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. , 1999, Haematologica.
[50] Beyond the FAB classification for myelodysplastic syndromes. , 1999, Haematologica.
[51] H. Mizoguchi,et al. Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. , 1999, Leukemia research.
[52] E. Ascari,et al. The myelodysplastic syndromes: predictive value of eight prognostic systems in 143 cases from a single institution. , 1999, Haematologica.
[53] K. Metze,et al. The differential diagnosis between aplastic anemia and hypocellular myelodysplasia in patients with pancytopenia. , 1999, Haematologica.
[54] F. Giles,et al. The potential of amifostine: from cytoprotectant to therapeutic agent. , 1999, Haematologica.
[55] Combined use of erythropoietin and G-CSF in the treatment of myelodysplastic syndromes. , 1999, Haematologica.
[56] J. Juncà,et al. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. , 1999, Haematologica.
[57] S. Magalhães,et al. p53 overexpression in refractory anemia. An immunohistochemical analysis of bone marrow biopsies. , 1999, Haematologica.
[58] P. Iversen,et al. Modulation of granulocyte-macrophage colony-stimulating factor gene expression by a tumor necrosis factor specific ribozyme in juvenile myelomonocytic leukemic cells. , 1998, Blood.
[59] Hepburn,et al. Poor response rate to a continuous schedule of Amifostine therapy for ‘low/intermediate risk’ myelodysplastic patients , 1998, British journal of haematology.
[60] C. Eaves,et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. , 1998, Blood.
[61] S. Scherer,et al. Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. , 1998, Blood.
[62] C. de Angeli,et al. Exposure to myelotoxic agents and myelodysplasia: case–control study and correlation with clinicobiological findings , 1998, British journal of haematology.
[63] D. Horsman,et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. , 1998, Blood.
[64] D. Kirsch,et al. Tumor-suppressor p53: implications for tumor development and prognosis. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] R. Davis,et al. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. , 1998, Leukemia research.
[66] Caillot,et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study , 1998, British journal of haematology.
[67] M. Lazzarino,et al. Randomized clinical study comparing aggressive chemotherapy with or without G‐CSF support for high‐risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS , 1998, British journal of haematology.
[68] K. Shannon,et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. , 1998, Blood.
[69] A. Gratwohl,et al. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey , 1998, Bone Marrow Transplantation.
[70] B. Quesnel,et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. , 1998, Blood.
[71] P. Nowell,et al. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[72] M. Cazzola,et al. Red blood cell precursor mass as an independent determinant of serum erythropoietin level. , 1998, Blood.
[73] S. Minucci,et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.
[74] V. Najfeld,et al. Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer , 1998, Leukemia.
[75] J. Čermák,et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow , 1998, British journal of haematology.
[76] D. Gilliland,et al. X-inactivation analysis in the 1990s: promise and potential problems , 1998, Leukemia.
[77] M. Labopin,et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome , 1998, Bone Marrow Transplantation.
[78] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[79] C. Preudhomme,et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. , 1998, Blood.
[80] Luoping Zhang,et al. Benzene metabolites induce the loss and long arm deletion of chromosomes 5 and 7 in human lymphocytes. , 1998, Leukemia research.
[81] Y Yoshida,et al. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. , 1998, Haematologica.
[82] E. Estey,et al. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. , 1998, Leukemia & lymphoma.
[83] U. Germing,et al. Increasing incidence of myelodysplastic syndromes: real or fictitious? , 1998, Leukemia research.
[84] M. Cazzola,et al. A patient-oriented approach to treatment of myelodysplastic syndromes. , 1998, Haematologica.
[85] K. Shannon,et al. Mutations of the NF 1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis , Type 1 , 1998 .
[86] P. Greenberg,et al. Prognostic factors and scoring systems in myelodysplastic syndromes. , 1998, Haematologica.
[87] A. Aventín,et al. Molecular delineation of 13q deletion boundaries in 20 patients with myeloid malignancies. , 1998, Blood.
[88] N. Young,et al. Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.
[89] B. Czepulkowski,et al. Fludarabine, cytarabine, G‐CSF and idarubicin (FLAG‐IDA) for the treatment of poor‐risk myelodysplastic syndromes and acute myeloid leukaemia , 1997, British journal of haematology.
[90] G. Nucifora. The EVI1 gene in myeloid leukemia , 1997, Leukemia.
[91] K. Hirokawa,et al. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes , 1997, Leukemia.
[92] M. Labopin,et al. Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS , 1997 .
[93] N. Zhao,et al. dic(5;17): A recurring abnormality in malignant myeloid disorders associated with mutations of TP53 , 1997, Genes, chromosomes & cancer.
[94] P. Greenberg,et al. Erythroid response to treatment with G‐CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model , 1997, British journal of haematology.
[95] A. List,et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. , 1997, Blood.
[96] P. Thall,et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. , 1997, Blood.
[97] C. Pui,et al. Juvenile myelomonocytic leukemia. , 1997, Blood.
[98] M. Cazzola,et al. Use of recombinant human erythropoietin outside the setting of uremia. , 1997, Blood.
[99] J. D. Vos,et al. Fas/Apo-1(CD95) expression and apoptosis in patients with myelodysplastic syndromes , 1997, Leukemia.
[100] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.
[101] J. Harbott,et al. Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases. , 1997 .
[102] W. Hiddemann,et al. S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes , 1997, Annals of Hematology.
[103] J. G. van den Tweel,et al. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome , 1997, Cancer.
[104] J. Sierra,et al. 192 Bone marrow transplantation for myelodysplasia: The IBMTR data , 1997 .
[105] F. Aversa,et al. 194 Myelodysplastic syndrome or leukemia developing after MDS treated by allogeneic bone marrow transplantation: Outcome of 90 adult patients , 1997 .
[106] U. Germing,et al. 169 Aggressive chemotherapy in MDS: The Düsseldorf experience , 1997 .
[107] M. Slovak,et al. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. , 1997, American journal of clinical pathology.
[108] R. Storb,et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. , 1997, Blood.
[109] S. Scherer,et al. Molecular cytogenetic delineation of deletions and translocations involving chromosome band 7q22 in myeloid leukemias. , 1997, Blood.
[110] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[111] L. Michaux,et al. 5q-, twenty-five years later: a synopsis. , 1997, Cancer genetics and cytogenetics.
[112] W. Friedrich,et al. Allogeneic bone marrow transplantation for chronic myelomonocytic leukemia in childhood: a report from the European Working Group on Myelodysplastic Syndrome in Childhood. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[113] A. Ganser,et al. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. , 1997, Leukemia & lymphoma.
[114] R. Darley,et al. The molecular basis of myelodysplastic syndromes. , 1997, Haematologica.
[115] D. Ross. Metabolic basis of benzene toxicity , 1996, European journal of haematology. Supplementum.
[116] S. Ben-Neriah,et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. , 1996, Blood.
[117] Martyn T. Smith,et al. Overview of benzene‐induced aplastic anaemia , 1996, European journal of haematology. Supplementum.
[118] F. Benvenuto,et al. IN VIVO MOBILIZATION OF KARYOTyPICALLY NORMAL PERIPHERAL BLOOD PROGENITOR CELLS IN HIGH‐RISK MDS, SECONDARY OR THERAPY‐RELATED ACUTE MYELOGENOUS LEUKAEMIA , 1996, British journal of haematology.
[119] E. Estey,et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. , 1996, Blood.
[120] C. Bloomfield,et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] J. Mary,et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors , 1996, The Lancet.
[122] H. Hasle,et al. Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia. , 1996, Leukemia.
[123] Marie-Cécile Michallet,et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle , 1996 .
[124] H. Koeffler,et al. Differentiation therapy in myelodysplastic syndromes. , 1996, Seminars in hematology.
[125] T. Petrella,et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. , 1996, British Journal of Cancer.
[126] M. Leppert,et al. Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2. , 1996, Blood.
[127] P. Greenberg,et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. , 1996, Blood.
[128] S. Scherer,et al. Molecular definition of a narrow interval at 7q22.1 associated with myelodysplasia. , 1996, Blood.
[129] P. Morel,et al. Cytogenetics of myelodysplastic syndromes. , 1996, Seminars in hematology.
[130] K. Kojima,et al. Low-dose melphalan for treatment of high-risk myelodysplastic syndromes. , 1996, Leukemia.
[131] K. Sullivan,et al. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS‐related acute myeloid leukaemia , 1996, British journal of haematology.
[132] R. Larson,et al. Therapy-related myeloid leukemia. , 2008, Seminars in oncology.
[133] F. Leeuwen. 4 Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment , 1996 .
[134] N. Zeleznik-Le,et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. , 1996, Blood.
[135] T. Jacks,et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells , 1996, Nature Genetics.
[136] A. Pession,et al. Role of allogeneic bone marrow transplantation from an HLA‐identical sibling or a matched unrelated donor in the treatment of children with juvenile chronic myeloid leukaemia , 1996, British journal of haematology.
[137] G. Verhoef,et al. Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor‐risk myelodysplastic syndromes , 1996, British journal of haematology.
[138] F. Appelbaum,et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] K. Sullivan,et al. Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors. , 1996, Blood.
[140] R. Latagliata,et al. Erythropoietin in myelodysplastic syndromes: durable response in a young patient. , 1996, Haematologica.
[141] C. Chastang,et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. , 1996, Blood.
[142] C. Mecucci,et al. Translocation (Y;1)(q12;q12) in hematologic malignancies. Report on two new cases, FISH characterization, and review of the literature. , 1996, Cancer genetics and cytogenetics.
[143] F. V. van Leeuwen. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. , 1996, Bailliere's clinical haematology.
[144] P. Greenberg,et al. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. , 1996, Blood.
[145] A. Nademanee,et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[146] G. Verhoef,et al. Polyclonal primitive hematopoietic progenitors can be detected in mobilized peripheral blood from patients with high-risk myelodysplastic syndromes. , 1995, Blood.
[147] H. Zwierzina,et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). , 1995, Leukemia.
[148] P. Nowell,et al. Physical mapping of the minimal region of loss in 5q- chromosome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[149] G. Dini,et al. Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone. , 1995, Blood.
[150] P. Marynen,et al. TEL gene is involved in myelodysplastic syndromes with either the typical t(5;12)(q33;p13) translocation or its variant t(10;12)(q24;p13). , 1995, Blood.
[151] K. Shannon,et al. Childhood monosomy 7: epidemiology, biology, and mechanistic implications. , 1995, Blood.
[152] C. Lorthois,et al. Exposure to occupational and environmental factors in myelodysplastic syndromes. Preliminary results of a case-control study. , 1995, Leukemia.
[153] E. Wattel,et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations. , 1995, Leukemia.
[154] M. Carlsson,et al. Incidence of myelodysplastic syndromes in a Swedish population , 1995, European journal of haematology.
[155] F. Locatelli,et al. Myelodysplastic syndromes: the pediatric point of view. , 1995, Haematologica.
[156] C. Mecucci. FISH (fluorescent in situ hybridization): the second youth of cytogenetics. , 1995, Haematologica.
[157] P. Emanuel,et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. , 1994, The New England journal of medicine.
[158] K. Shannon,et al. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21ras , 1994 .
[159] J. Boultwood,et al. The 5q-syndrome. , 1994, Blood.
[160] R. Gutzmer,et al. Life expectancy in primary myelodysplastic syndromes: A prognostic score based upon histopathology from bone marrow biopsies of 569 patients , 1994, European journal of haematology.
[161] D. T. Goodhead,et al. α-particle-induced chromosomal instability in human bone marrow cells , 1994, The Lancet.
[162] R. Gale,et al. Hematologic Abnormalities in Fanconi Anemia: An International Fanconi Anemia Registry Study , 1994 .
[163] P. Greenberg,et al. Expression of EVI1 in myelodysplastic syndromes and other hematologic malignancies without 3q26 translocations. , 1994, Blood.
[164] D. Oscier,et al. Establishing the incidence of myelodysplastic syndrome , 1994 .
[165] C. Preudhomme,et al. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. , 1994, Leukemia.
[166] A. Green,et al. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. , 1994, Blood.
[167] P. Thall,et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[168] N. Young,et al. Gamma-Interferon Gene Expression in the Bone Marrow of Patients with Aplastic Anemia , 1994, Annals of Internal Medicine.
[169] P. O'Connell,et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. , 1994, The New England journal of medicine.
[170] G. Brodeur. The NF1 gene in myelopoiesis and childhood myelodysplastic syndromes. , 1994, The New England journal of medicine.
[171] Yoshiyuki Kobayashi,et al. Trilineage recovery by combination therapy with recombinant human granulocyte colony‐stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia , 1994, Stem cells.
[172] H. Johnsen,et al. Recombinant human granulocyte‐macrophage colony‐stimulating factor plus recombinant human erythropoietin may improve anemia in selected patients with myelodysplastic syndromes , 1993, American journal of hematology.
[173] A. Tichelli,et al. Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. , 1993, The New England journal of medicine.
[174] I. Dybedal,et al. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes. , 1993, Leukemia & lymphoma.
[175] A. Duhamel,et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.
[176] J. Wallvik,et al. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. , 1993, Leukemia.
[177] J. Buckley,et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[178] P. Greenberg,et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. , 1993, Blood.
[179] F. Appelbaum,et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. , 1993, Blood.
[180] R. Espinosa,et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[181] S. Asano,et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. , 1993, Leukemia.
[182] J. Hansen,et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. , 1993, The New England journal of medicine.
[183] A. Kanamaru,et al. [Bone marrow transplantation for refractory anemia]. , 1993, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[184] R. Berger,et al. Interphase cytogenetics by fluorescent in situ hybridization (FISH) for characterization of monosomy-7-associated myeloid disorders. , 1993, Leukemia.
[185] C. Campagnoli,et al. Bone marrow transplantation from unrelated donor in myelodysplastic syndromes. , 1993, Bone marrow transplantation.
[186] Y. Kan,et al. Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7. , 1992, Genomics.
[187] M. Mittelman,et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. , 1992, Blood.
[188] O. Haas,et al. Experience in pediatric myelodysplastic syndromes. , 1992, Hematology/oncology clinics of North America.
[189] C. Bloomfield,et al. Trisomy 13 in acute leukemia. , 1992, Leukemia & lymphoma.
[190] P. O'Connell,et al. Monosomy 7 myeloproliferative disease in children with neurofibromatosis, type 1: epidemiology and molecular analysis. , 1992, Blood.
[191] Z. Estrov,et al. Central role of tumour necrosis factor, GM‐CSF, and interleukin 1 in the pathogenesis of juvenile chronic myelogenous leukaemia , 1992, British journal of haematology.
[192] U. Germing,et al. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. , 1992, Leukemia.
[193] G Barosi,et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. , 1992, Blood.
[194] P. Emanuel,et al. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. , 1991, Experimental hematology.
[195] D. Anderson,et al. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. , 1991, British journal of industrial medicine.
[196] P. Morel,et al. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy , 1991, British journal of haematology.
[197] F. Behm,et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy , 1991, The Lancet.
[198] F. Tamanoi,et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae , 1990, Cell.
[199] R. Gelber,et al. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[200] C. Haanen,et al. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia , 1990, Cancer.
[201] S. Raimondi,et al. Myeloid neoplasia in children treated for solid tumours , 1990, The Lancet.
[202] B. Cheson,et al. The myelodysplastic syndromes: current approaches to therapy. , 1990, Annals of internal medicine.
[203] M. Sanz,et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors , 1990, British journal of haematology.
[204] R. Storb,et al. Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. , 1990 .
[205] A. Gratwohl,et al. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG) , 1990, British journal of haematology.
[206] N. Day,et al. Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.
[207] J. Goasguen,et al. Prognostic factors of myelodysplastic syndromes--a simplified 3-D scoring system. , 1990, Leukemia research.
[208] P. Emanuel,et al. Granulocyte-macrophage colony-stimulating factor is an endogenous regulator of cell proliferation in juvenile chronic myelogenous leukemia. , 1989, Blood.
[209] F. Behm,et al. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. , 1989, The New England journal of medicine.
[210] M. Sanz,et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.
[211] E. Guinan,et al. Bone marrow transplantation for children with myelodysplastic syndromes. , 1989, Blood.
[212] R. Truitt,et al. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[213] R. Larson,et al. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine. , 1988, Blood.
[214] F. Mitelman,et al. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes , 1988, European journal of haematology.
[215] R. Parmley,et al. Cell culture studies and oncogene expression in juvenile chronic myelogenous leukemia. , 1988, Experimental hematology.
[216] J. Bennett. Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Cooperative Study Group. , 1988, Cancer genetics and cytogenetics.
[217] K. Sullivan,et al. Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia. , 1988, Blood.
[218] J. Gmür. [Allogeneic bone marrow transplantation]. , 1988, Therapeutische Umschau. Revue therapeutique.
[219] A. Avilés,et al. [Treatment of myelodysplastic syndromes with danazol]. , 1988, Archivos de investigacion medica.
[220] Z. Estrov,et al. Juvenile Chronic Myelogenous Leukemia , 1988, The American journal of pediatric hematology/oncology.
[221] D. Oscier. Myelodysplastic syndromes. , 2007, Bailliere's clinical haematology.
[222] B. Coiffier,et al. Myelodysplastic syndromes. A multiparametric study of prognostic factors in 336 patients , 1987, Cancer.
[223] Z. Estrov,et al. The value of intensive combination chemotherapy for juvenile chronic myelogenous leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[224] P. Bierman,et al. Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[225] Z. Estrov,et al. Residual juvenile chronic myelogenous leukemia cells detected in peripheral blood during clinical remission. , 1987, Blood.
[226] W. Moloney,et al. Radiogenic leukemia revisited. , 1987, Blood.
[227] L. Parapia,et al. Successful oral chemotherapy with idarubicin in refractory anaemia with excess blasts , 1987, European journal of haematology.
[228] D. Oscier. 5 Myelodysplastic syndromes , 1987 .
[229] B. Cheson,et al. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. , 1987, Seminars in oncology.
[230] J. Pedersen‐Bjergaard,et al. Cytogenetic characteristics of therapy‐related acute nonlymphocytic leukaemia, preleukaemia and acute myeloproliferative syndrome: correlation with clinical data for 61 consecutive cases , 1987, British journal of haematology.
[231] G. Tricot,et al. A chromosomal profile of polycythemia vera. , 1987, Cancer genetics and cytogenetics.
[232] G. Masera,et al. Myelodysplastic Syndromes in Childhood: Report of 21 Patients from Italy and West Germany , 1987, The American journal of pediatric hematology/oncology.
[233] R. Larson,et al. High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study , 1986, American journal of hematology.
[234] Z. Estrov,et al. Juvenile chronic myelogenous leukemia: characterization of the disease using cell cultures. , 1986, Blood.
[235] G. Tricot,et al. An identical translocation between chromosome 1 and 15 in two patients with myelodysplastic syndromes , 1986, British journal of haematology.
[236] G. Tricot,et al. The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.
[237] G. Tricot,et al. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis , 1985, British journal of haematology.
[238] G. Tricot,et al. The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations , 1985, British journal of haematology.
[239] D. Machin,et al. Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.
[240] H. Deeg,et al. Allogeneic marrow transplantation in the treatment of preleukemia. , 1984, Annals of internal medicine.
[241] Denis R. Miller,et al. Subacute and chronic myelomonocytic leukemia in children (juvenile CML). Clinical and hematologic observations, and identification of prognostic factors , 1984, Cancer.
[242] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.
[243] B. Lange,et al. Preleukemia in children. , 1981, The Journal of pediatrics.
[244] R. Mertelsmann,et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. , 1980, Blood.
[245] J. Lilleyman,et al. Treatment of juvenile chronic myeloid leukemia with sequential subcutaneous cytarabine and oral mercaptopurine. , 1977, Blood.
[246] A. Chapelle,et al. Defective chemotaxis in monosomy-7 , 1977, Nature.
[247] J. Fryns,et al. Distinct haematological disorder with deletion of long arm of No. 5 chromosome , 1974, Nature.